Azul Bio Research leverages cutting-edge genomics and synthetic biology to design next-generation therapeutics for complex global health challenges.
Patents Pending
Therapeutic Candidates
% Target Precision
M+ Funding Raised
At Azul Bio Research, we believe the answers to humanity's most pressing medical challenges are written in the genetic code. By combining machine learning with molecular engineering, we accelerate the discovery of targeted therapies to treat diseases once thought untreatable.
We are a multidisciplinary team of biologists, computer scientists, and clinical researchers operating at the intersection of information theory and molecular physics.
Atom-level engineering for ultra-targeted drug delivery systems.
Restoring natural cellular pathways via genetic therapeutics.
Our scientific ecosystem targets diverse therapeutic modalities using advanced delivery frameworks.
Utilizing neural networks to model structural biology and predict how proteins interact with novel therapeutic compounds at the atomic level.
Learn MoreProgramming instructions for cells to manufacture their own medicine, enabling temporary and highly adjustable treatments for severe genetic anomalies.
Learn MoreReprogramming the patient's immune cells using advanced synthetic biological receptors to neutralize solid tumors and autoimmune disorders.
Learn MoreTrack our developmental progress from target discovery through ongoing clinical trials.
| Program ID | Target Indication | Modality | Discovery | Pre-Clinical | Phase I | Phase II |
|---|---|---|---|---|---|---|
| AZL-092 | Refractory Glioblastoma | Synthetic Immune | Discovery | Pre-Clinical | Phase I | Phase II |
| AZL-104 | Cardiomyopathy (Genetic) | mRNA Therapeutic | Discovery | Pre-Clinical | Phase I | Phase II |
| AZL-312 | Sarcopenia / Muscle Loss | Gene Discovery | Discovery | Pre-Clinical | Phase I | Phase II |
| AZL-501 | Autoimmune Encephalitis | Synthetic Immune | Discovery | Pre-Clinical | Phase I | Phase II |
Our proprietary AI computational suite models the physical dynamics of complex molecules. This eliminates typical trial-and-error laboratory cycles, allowing us to accurately simulate compound efficacy in silico prior to chemical synthesis.
Simulate protein folding structures in seconds rather than months of experimental crystallography.
Fine-tune molecular binding receptors to maximize target efficacy while eliminating off-target toxicities.
We partner with leading academic institutions, biopharmaceutical corporations, and visionary investors to advance life-changing scientific breakthroughs.